Daiichi Sankyo Plays Long Game With Quizartinib Outside Japan

 
• By Maureen Kenny

Japanese company Daiichi Sankyo has its eye on first-line FLT3-ITD AML indication after rejection of relapsed/refractory plans in EU and US.

Action_Plan
Daiichi will wait for results from QuANTUM-First to determine next steps for quizartinib • Source: Shutterstock

More from Europe

More from Geography